Pipeline: New therapies to come for debilitating eye diseases

,

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan